Acute myeloid leukemia market to be worth $1.67 billion by 2020

The market for acute myeloid leukemia therapeutics market in the G8 countries (USA, Canada, UK, Germany, Italy, France, Spain and Japan) was valued at $216 million in 2010 and is expected to grow at a CAGR of 28.40% from 2015 to 2020, to reach a value of $1.67 billion, according to a new report added to the offering of Markets and Markets.

The report studies four existing regimens and single drugs for acute myeloid leukemia market. Currently, there are four major drugs in pipeline for acute myeloid leukemia; which are expecting a market launch by 2012-2014. Quizartinib is currently in Phase II pivotal clinical trial for the relapsed/refractory AML patient; which will be launched in the market in 2012 by Ambit Biosciences. Quizartinib has received Orphan Drug designation grant from US Food and Drug Administration and the European Union. Besides, the drug has obtained fast track designation in the USA in 2010 for the treatment of FLT3-ITD positive patients with relapsed/refractory AML. The drug is expected to be priced at $25,448 for a year’s therapy for patients who take the product.

The market was dominated by AVD (Adriamycin, vinblastine and dacarbazine) regimen in 2010. AVD regimen accounted for the largest share; ie, 54.08% of the acute myeloid leukemia therapeutics market in G8 Countries in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, cytarabine and quizartinib, with sales amounting to $698 million, $285 million, and $234 million respectively.